TickerGuard
Buy Day today: Poor (44) Weak market breadth · today: Core PCE (August) ≈
RXRX

Recursion Pharmaceuticals Inc

Healthcare · Biotechnology

3.70$ -8.6% vs. previous close Closing price · As of: Sep 23, 2026

Statements

Balance Sheet

All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.

Tick rows to compare them in a chart (up to 4)

Balance Sheet RXRX
Line item 2019 2020 2021 2022 2023 2024 2025
– +194.4% +104.4% +14.9% -6.8% +121.6% +1.8%
– +248.7% +100.7% +6.6% -23.1% +63.0% +13.8%
– +275.1% +8.8% +92.9% -28.8% +51.8% +25.1%
– +275.1% +97.1% +6.5% -28.8% +51.8% +25.1%
– +3.3% +5,726.9% -69.7% +12.4% +1,489.1% -49.9%
– -4.7% -69.2% -17.5% -341.7% – –
– +6.6% +149.3% +87.6% – – –
– – +0.0% +0.0% +6,398.9% +186.0% +8.9%
– – -18.0% -5.7% +2,690.4% +821.6% -7.7%
– +123.7% -86.6% +219.7% -11.7% +117.5% -17.0%
– +245.6% +102.0% +114.9% -7.1% +101.2% -21.2%
– +183.1% -2.2% +301.7% +1.8% +260.9% -2.1%
– -14.8% +162.5% +62.7% -13.8% +446.7% -16.2%
– -8.1% -94.5% -15.3% +105.4% +1,627.7% -49.7%
– – – -10.5% -4.6% +123.3% +9.3%
– – – – – – –
– +0.0% +2.7% +3.1% +18.4% +31.9% +63.2%

Data as of: September 23, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?